Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    1.00 (0.07%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Apr 20219:19 amRNSTotal Voting Rights
17th Mar 20212:29 pmRNSDirector/PDMR Shareholding
17th Mar 202111:08 amRNSAnnual Financial Report
15th Mar 202111:24 amRNSDirector/PDMR Shareholding
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition
2nd Mar 20214:44 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:01 pmRNSDirector/PDMR Shareholding
25th Feb 20211:00 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSFinal Results
8th Feb 20212:55 pmRNSNotice of Results
26th Jan 20218:01 amRNSPotential Acquisition
15th Jan 20213:59 pmRNSHikma provides update on generic Advair Diskus®
13th Jan 20219:21 amRNSDirector/PDMR Shareholding
13th Jan 20219:14 amRNSDirector/PDMR Shareholding
18th Dec 202010:10 amRNSHolding(s) in Company
17th Dec 20205:30 pmRNSHikma launches generic Advair Diskus®
14th Dec 202012:57 pmRNSHolding(s) in Company
10th Dec 20204:00 pmRNSDirector/PDMR Shareholding
10th Dec 20203:51 pmRNSDirector/PDMR Shareholding
2nd Dec 20203:00 pmRNSTotal Voting Rights
2nd Dec 20201:05 pmRNSHolding(s) in Company
9th Nov 202011:38 amRNSHolding(s) in Company
5th Nov 202011:30 amRNSDirectorate Change
5th Nov 20207:00 amRNSHikma launches Icosapent Ethyl Capsules
5th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:20 pmRNSTotal Voting Rights
22nd Oct 20201:16 pmRNSNotice to Bondholders
8th Oct 20208:38 amRNSBlocklisting Application
1st Oct 202011:01 amRNSBlock listing Interim Review
22nd Sep 20207:00 amRNSHikma updates on ANDA for generic Advair Diskus®
3rd Sep 20203:15 pmRNSHikma receives favourable court ruling
2nd Sep 20209:30 amRNSTotal Voting Rights
7th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20202:25 pmRNSTotal Voting Rights
16th Jul 202012:06 pmRNSNotice of Results
7th Jul 202012:48 pmRNSPublication of Offering Circular
25th Jun 20204:12 pmRNSHolding(s) in Company
25th Jun 20201:00 pmRNSDirectorate Change
23rd Jun 20205:30 pmRNSHikma Pharmaceuticals
23rd Jun 202011:39 amRNSHolding(s) in Company
23rd Jun 20207:00 amRNSTransaction in Own Shares
23rd Jun 20207:00 amRNSResult of placing in Hikma Pharmaceuticals PLC
22nd Jun 20205:13 pmRNSTransaction in Own Shares
22nd Jun 20205:09 pmRNSProposed Placing in Hikma Pharmaceuticals PLC
22nd Jun 202011:24 amRNSDirector/PDMR Shareholding
22nd Jun 202011:22 amRNSDirector/PDMR Shareholding
22nd Jun 202011:20 amRNSDirector/PDMR Shareholding
2nd Jun 20209:31 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.